Roche outbid competing biopharma to secure Spark deal
In gene editing milestone, first patient treated in Vertex, CRISPR Therapeutics study
Roche Makes $4.8 Billion Bid for Spark Therapeutics and Its Gene Therapy Programs
Novo Nordisk nabs FDA nod for hemophilia A drug Esperoct but can’t launch until 2020
Johnson & Johnson dips a toe into gene therapy
Uniqure turns the screw on Spark and Pfizer
Έγκριση σε νέα θεραπεία για αποκατάσταση της όρασης στην Ε.Ε.
Janssen and MeiraGTx Sign $440 Million Deal to Develop Gene Therapies for Eye Diseases
Gene therapy: how much will it cost patients?
PhRMA Highlights Impact of Cell and Gene Therapies in New Report
Looking into the Crystal Ball: Top Predictions for 2019 by Biopharma Execs
As gene therapy gains traction, it is expected to create a number of job opportunities. For example, the UK government projects gene and cell therapy in Britain alone will create 18,000 new … Continue Reading Gene Therapy, Gene Editing and Immuno-Oncology Creating Thousands of New Job Opportunities
Amicus muscles in on Pompe gene therapy chase
Gene therapy deal-making shows no signs of stopping
With Hemlibra, Roche seeks to break into tight hemophilia circle
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs. It was pretty obvious four … Continue Reading Taking a Look at Trends in Biotherapeutics